Country: Armenia
Language: English
Source: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում
isoflurane
Piramal Pharma Limited
N01AB06
isoflurane
100%
liquid for inhalation
250ml glass bottle
Prescription
Registered
2023-08-05
“Prescription medicine. Only for hospital use in anaesthesiology”. ISOFLURANE, 100% INHALATION VAPOUR, LIQUID COMPOSITION AND DESCRIPTION Isoflurane is a colourless non-flammable general inhalation anaesthetic which contains no additive or stabiliser. It is 1-chloro-2,2,2- trifluoroethyl difluoromethyl ether. PHARMACOTHERAPEUTIC GROUP : Nervous system; anaesthetic; general; Halogenated hydrocarbons ATC CODE: N01AB06 INDICATIONS Isoflurane is general inhalation anaesthetic for use in induction and maintenance. CONTRAINDICATIONS Isoflurane is contraindicated in patients with known sensitivity to Isoflurane or to other halogenated anaesthetics. It is also contraindicated in patients with known or suspected genetic susceptibility to malignant hyperthermia. PRECAUTIONS: Vaporisers specially calibrated for isoflurane should be used so that the concentration of anaesthetic delivered can be accurately controlled. Hypotension and respiratory depression increase as anaesthesia is deepened. Reports of QT prolongation, associated with torsade depointes (in exceptional cases, fatal), have been received. Caution should be exercised when administering isoflurane to patients at risk of QT prolongation. Caution should be exercised in administering general anaesthesia, including isoflurane, to patients with mitochondrial disorders. Isoflurane, like other inhalational agents, has relaxant effects on the uterus with the potential risk for uterine bleeding. Clinical judgement should be observed when using isoflurane during obstetric anaesthesia. Consideration should be taken to use the lowest possible concentration of isoflurane in obstetrical operations (see ‘pregnancy’). Isolated cases of increased carboxyhaemoglobin have been reported with the use of halogenated inhalation agents with a –CF 2 H moiety (i.e., desflurane, enflurane and isoflurane). No clinically significant concentrations of carbon monoxide are produced in the presence of normally hydrated absorbents. Care should be taken to follow manufacturer’s instruc Read the complete document
SUMMARY OF PRODUCT CHARACTERISTICS (SMPC) 1. NAME OF THE MEDICINAL PRODUCT Isoflurane 100% Inhalation Vapour liquid. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Isoflurane is a colourless non-flammable general inhalation anaesthetic which contains no additive or stabiliser. It is 1-chloro-2,2,2- trifluoroethyldifluoromethyl ether. 3. PHARMACEUTICAL FORM Liquid for inhalation 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Isoflurane is general inhalation anaesthetic for use ininduction and maintenance. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology MAC values for Isoflurane vary with age. The table below indicates average MAC values for different age groups. ADULTS AGE AVERAGE MAC VALUE IN 100% OXYGEN 70% N2O 26 ± 4 years 1.28% 0.56% 44 ± 7 years 1.15% 0.50% 64 ± 5 years 1.05% 0.37% PAEDIATRIC POPULATION AGE AVERAGE MAC VALUE IN 100% OXYGEN Preterm neonates < 32 weeks gestational age 1.28% Preterm neonates 32-37 weeks gestational age 1.41% 0-1 month 1.60% 1-6 months 1.87% 6-12 months 1.80% 1-5 years 1.60% Premedication: Premedication drugs should be selected according to the needs of the patient. The respiratory depressant effect of Isoflurane should be taken into account. The use of anticholinergic drugs is a matter of choice, but may we advisable for inhalation induction in paediatrics. Induction: As Isoflurane has a mild pungency, inhalation should usually be preceded by the use of a short acting barbiturate, or other intravenous induction agent, to prevent coughing. Alternatively, Isoflurane with oxygen or with an oxygen/ nitrous oxide mixture may be administered. It is recommended that induction with Isoflurane be initiated at a concentration of 0.5%. Concentrations of 1.5-3.0% usually produce surgical anaesthesia in 7-10 minutes. Induction of anaesthesia in children: Isoflurane is not recommended for use as an inhalation induction agent in infants and children because of the occurrence of cough, breath-holding, desaturation, increased secretions and laryngospasm. Maintenance: Adequate anaesthesia Read the complete document